Keywords: azilect, helps, double, 2nd-line, mao-bs, pd, decision

Azilect helps "double 2nd-line MAO-Bs in PD"

Article | 16 March 2009

• Print This

Decision Resources says that second-line Parkinson's disease patient's share of monoamine oxidase-B inhibitors has increased from 14.1% to 35.2% since last year.

Enjoying this article? To continue reading you need to login or subscribe.